IBD ( Inflammatory Bowel Disease )

Inflammatory Bowel Disease (IBD) is a term used to describe disorders that involve chronic inflammation of the digestive tract, including Crohn's Disease and Ulcerative Colitis. Below are COVID news and research updates that specifically relate to IBD.

COVID-19 Vaccination in Adults with Inflammatory Bowel Disease

A recent review article covers current knowledge about COVID-19 vaccination in those with inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis. The authors concluded that IBD patients are not at increased risk of infection or serious illness from Covid-19. With the exception of patients taking corticosteroids, most IBD therapies have been shown not to increase the risk of covid-19.

Read More »

Caring for Autoimmunity & Long COVID with a Personalized Approach

The company Mymee recently published a study on their personalized digital care program for patients living with autoimmune diseases as well as long Covid. Researchers found that over 85% of patients with moderate to severe symptoms saw improvements with their anxiety, depression, fatigue, pain interference, sleep disturbance, and pain intensity while increasing cognitive and physical function.

Read More »

COVID-19 in Patients with Systemic Autoimmune Rheumatic Diseases

Researchers evaluated the characteristics, severity, course of infection, and disease outcomes in COVID-19 patients with and without Systemic Autoimmune Rheumatic Diseases (SARDs). Patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), Sjögren’s syndrome, Psoriasis, Type 1 Diabetes, Inflammatory Bowel Disease, and Glomerulonephritis, amongst others, were included in the study. 

Read More »

Covid-19 Outcomes in Autoimmune Disease Patients

Autoimmune disease is currently considered a risk factor for severe COVID-19. A research article published in Rheumatology last Fall summarized 30-day outcomes of autoimmune disease (AD) patients following hospitalization with COVID-19. AD patients diagnosed and/or hospitalized between January and June 2020 with COVID-19 were included, and their 30 day outcomes were compared to patients with at least one AD hospitalized with influenza from September 2017 through April 2018.

Read More »